Cargando…
Effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation
PURPOSE: Although patients with tuberculous destroyed lung (TDL) receive long-acting muscarinic antagonist (LAMA) inhaler therapy, its effectiveness is not clear. This study evaluated the effect of LAMA inhaler therapy on mortality in patients with TDL and airflow limitation. PATIENTS AND METHODS: A...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407515/ https://www.ncbi.nlm.nih.gov/pubmed/30881003 http://dx.doi.org/10.2147/TCRM.S194324 |
_version_ | 1783401570680963072 |
---|---|
author | Kim, Ho Cheol Kim, Tae Hoon Rhee, Chin Kook Han, Minkyu Oh, Yeon-Mok |
author_facet | Kim, Ho Cheol Kim, Tae Hoon Rhee, Chin Kook Han, Minkyu Oh, Yeon-Mok |
author_sort | Kim, Ho Cheol |
collection | PubMed |
description | PURPOSE: Although patients with tuberculous destroyed lung (TDL) receive long-acting muscarinic antagonist (LAMA) inhaler therapy, its effectiveness is not clear. This study evaluated the effect of LAMA inhaler therapy on mortality in patients with TDL and airflow limitation. PATIENTS AND METHODS: A retrospective cohort of 683 patients with TDL and airflow limitation was analyzed in this study. The mortality was compared between 177 patients treated with LAMA inhalers >360 days (LAMA group) and 506 patients not treated with LAMA inhalers or treated with LAMA inhalers for <360 days (non-LAMA group). Risk factors for mortality were analyzed with Cox proportional hazards models and survival analysis was performed after propensity score matching. RESULTS: Patients in the LAMA group appeared to have worse baseline characteristics, older mean age, lower lung function, higher X-ray severity, and were more likely to receive long-term oxygen therapy than those in the non-LAMA group. On multivariate analysis, LAMA inhaler usage was independently associated with lower risk of mortality (HR, 0.405; P=0.006) after adjusting age, gender, body mass index, smoking history, Charlson Comorbidity Index, lung function, X-ray severity, and long-term oxygen therapy. After propensity score matching to adjust for the above unbalanced baseline characteristics, patients in the LAMA group tended to have a better prognosis than those in the non-LAMA group (121 patients in each group, 5-year mortality rate: 2.5% vs 9.1%, P=0.057). If we performed the same analysis of propensity score matching even after excluding patients with corticosteroids/long-acting beta-2 agonist (ICS/LABA) usage, patients in the LAMA group had a better prognosis than those in the non-LAMA group (64 patients in each group, 5-year mortality rate: 3.1% vs 14.1%, P=0.039). CONCLUSION: LAMA inhaler treatment might reduce mortality in patients with TDL and airflow limitation. |
format | Online Article Text |
id | pubmed-6407515 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-64075152019-03-16 Effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation Kim, Ho Cheol Kim, Tae Hoon Rhee, Chin Kook Han, Minkyu Oh, Yeon-Mok Ther Clin Risk Manag Original Research PURPOSE: Although patients with tuberculous destroyed lung (TDL) receive long-acting muscarinic antagonist (LAMA) inhaler therapy, its effectiveness is not clear. This study evaluated the effect of LAMA inhaler therapy on mortality in patients with TDL and airflow limitation. PATIENTS AND METHODS: A retrospective cohort of 683 patients with TDL and airflow limitation was analyzed in this study. The mortality was compared between 177 patients treated with LAMA inhalers >360 days (LAMA group) and 506 patients not treated with LAMA inhalers or treated with LAMA inhalers for <360 days (non-LAMA group). Risk factors for mortality were analyzed with Cox proportional hazards models and survival analysis was performed after propensity score matching. RESULTS: Patients in the LAMA group appeared to have worse baseline characteristics, older mean age, lower lung function, higher X-ray severity, and were more likely to receive long-term oxygen therapy than those in the non-LAMA group. On multivariate analysis, LAMA inhaler usage was independently associated with lower risk of mortality (HR, 0.405; P=0.006) after adjusting age, gender, body mass index, smoking history, Charlson Comorbidity Index, lung function, X-ray severity, and long-term oxygen therapy. After propensity score matching to adjust for the above unbalanced baseline characteristics, patients in the LAMA group tended to have a better prognosis than those in the non-LAMA group (121 patients in each group, 5-year mortality rate: 2.5% vs 9.1%, P=0.057). If we performed the same analysis of propensity score matching even after excluding patients with corticosteroids/long-acting beta-2 agonist (ICS/LABA) usage, patients in the LAMA group had a better prognosis than those in the non-LAMA group (64 patients in each group, 5-year mortality rate: 3.1% vs 14.1%, P=0.039). CONCLUSION: LAMA inhaler treatment might reduce mortality in patients with TDL and airflow limitation. Dove Medical Press 2019-03-05 /pmc/articles/PMC6407515/ /pubmed/30881003 http://dx.doi.org/10.2147/TCRM.S194324 Text en © 2019 Kim et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Kim, Ho Cheol Kim, Tae Hoon Rhee, Chin Kook Han, Minkyu Oh, Yeon-Mok Effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation |
title | Effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation |
title_full | Effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation |
title_fullStr | Effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation |
title_full_unstemmed | Effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation |
title_short | Effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation |
title_sort | effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407515/ https://www.ncbi.nlm.nih.gov/pubmed/30881003 http://dx.doi.org/10.2147/TCRM.S194324 |
work_keys_str_mv | AT kimhocheol effectsofinhalertherapyonmortalityinpatientswithtuberculousdestroyedlungandairflowlimitation AT kimtaehoon effectsofinhalertherapyonmortalityinpatientswithtuberculousdestroyedlungandairflowlimitation AT rheechinkook effectsofinhalertherapyonmortalityinpatientswithtuberculousdestroyedlungandairflowlimitation AT hanminkyu effectsofinhalertherapyonmortalityinpatientswithtuberculousdestroyedlungandairflowlimitation AT ohyeonmok effectsofinhalertherapyonmortalityinpatientswithtuberculousdestroyedlungandairflowlimitation |